Table of Contents Author Guidelines Submit a Manuscript
Depression Research and Treatment
Volume 2014, Article ID 730505, 6 pages
http://dx.doi.org/10.1155/2014/730505
Clinical Study

Lovastatin as an Adjuvant to Lithium for Treating Manic Phase of Bipolar Disorder: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

1Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Psychiatry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
4Shiraz University of Medical Sciences, Shiraz, Iran
5Shiraz Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Received 14 February 2014; Revised 4 June 2014; Accepted 5 June 2014; Published 15 July 2014

Academic Editor: Janusz K. Rybakowski

Copyright © 2014 Ahmad Ghanizadeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Janney, Fagiolini A., H. A. Swartz et al., “Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry,” Journal of Affective Disorders, vol. 152–154, pp. 498–504, 2013. View at Publisher · View at Google Scholar
  2. F. A. Gomes, K. M. Almeida, P. V. Magalhães et al., “Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder,” Revista Brasileira de Psiquiatria, vol. 35, no. 2, pp. 126–130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Maina, E. Bechon, S. Rigardetto, and V. Salvi, “General medical conditions are associated with delay to treatment in patients with bipolar disorder,” Psychosomatics, vol. 54, no. 5, pp. 437–442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Lang, A. M. Barr, and R. M. Procyshyn, “Management of medication-related cardiometabolic risk in patients with severe mental illness,” Current Cardiovascular Risk Reports, vol. 7, no. 4, pp. 283–287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Brown, A. Barrett, E. Caffery et al., “Medication continuity among medicaid beneficiaries with Schizophrenia and bipolar disorder,” Psychiatric Services, vol. 64, no. 9, pp. 878–885, 2013. View at Publisher · View at Google Scholar
  6. D. Vancampfort, K. Vansteelandt, C. U. Correll et al., “Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators,” The American Journal of Psychiatry, vol. 170, no. 3, pp. 265–274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Andrade, Primary Prevention of Cardiovascular Events in Patients with Major Mental Illness: A Possible Role for Statins, Bipolar Disorder, 2013.
  8. C. Crump, K. Sundquist, M. A. Winkleby, and J. Sundquist, “Comorbidities and mortality in bipolar disorder: a Swedish national cohort study,” JAMA Psychiatry, vol. 70, no. 9, pp. 931–939, 2013. View at Publisher · View at Google Scholar
  9. J. Westman, J. Hällgren, K. Wahlbeck, D. Erlinge, L. Alfredsson, and U. Ösby, “Cardiovascular mortality in bipolar disorder: A population-based cohort study in Sweden,” BMJ Open, vol. 3, no. 4, Article ID e002373, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. M. Laursen, K. Wahlbeck, J. Hällgren et al., “Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries,” PLoS ONE, vol. 8, no. 6, Article ID e67133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Klawitter, I. Zafar, A. T. Pennington et al., “Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease,” BMC Nephrology, vol. 14, no. 1, article 165, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Kumar, N. Sharma, A. Gupta, H. Kalonia, and J. Mishra, “Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms,” Brain Research, vol. 1471, pp. 13–22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Reis, V. Estato, T. I. da Silva et al., “Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria,” PLoS Pathogens, vol. 8, no. 12, Article ID e1003099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. T. C. B. Piermartiri, C. P. Figueiredo, D. Rial et al., “Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β1−40 administration in mice: evidence for dissociation between cognitive deficits and neuronal damage,” Experimental Neurology, vol. 226, no. 2, pp. 274–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Parihar, M. S. Parihar, W. J. Zenebe, and P. Ghafourifar, “Statins lower calcium-induced oxidative stress in isolated mitochondria,” Human and Experimental Toxicology, vol. 31, no. 4, pp. 355–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Pfaffenseller, G. R. Fries, B. Wollenhaupt-Aguiar et al., “Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder,” Expert Review of Neurotherapeutics, vol. 13, no. 7, pp. 827–842, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Berk, F. Kapczinski, A. C. Andreazza et al., “Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors,” Neuroscience and Biobehavioral Reviews, vol. 35, no. 3, pp. 804–817, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ghanizadeh and M. Berk, “Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia,” Medical Gas Research, vol. 3, no. 1, p. 11, 2013. View at Google Scholar
  19. M. Leboyer, I. Soreca, J. Scott et al., “Can bipolar disorder be viewed as a multi-system inflammatory disease?” Journal of Affective Disorders, vol. 141, no. 1, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ghanizadeh and A. Hedayati, “Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial,” Depress Anxiety, vol. 30, no. 11, pp. 1084–1088, 2013. View at Google Scholar
  21. I. Mansi, C. R. Frei, M. J. Pugh, and E. M. Mortensen, “Psychologic disorders and statin use: a propensity score-matched analysis,” Pharmacotherapy, vol. 33, no. 6, pp. 615–626, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Lustman, S. Nakar, A. D. Cohen, and S. Vinker, “Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study,” Prostate Cancer and Prostatic Diseases, vol. 17, no. 1, pp. 6–9, 2014. View at Publisher · View at Google Scholar
  23. J. E. Berner, “Statins can produce ataxia in bipolar disorder: two case reports,” Journal of Clinical Psychiatry, vol. 71, no. 3, article 359, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. R. C. Young, J. T. Biggs, V. E. Ziegler, and D. A. Meyer, “A rating scale for mania: reliability, validity and sensitivity,” The British Journal of Psychiatry, vol. 133, no. 11, pp. 429–435, 1978. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Pacchiarotti, D. J. Bond, R. J. Baldessarini et al., “The International Society for Bipolar Disorders (ISBD) Task-Force report on antidepressant use in bipolar disorders,” The American Journal of Psychiatry, vol. 170, no. 11, pp. 1249–1262, 2013. View at Publisher · View at Google Scholar
  26. M. A. Omar, J. P. Wilson, and T. S. Cox, “Rhabdomyolysis and HMG-CoA reductase inhibitors,” Annals of Pharmacotherapy, vol. 35, no. 9, pp. 1096–1107, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Ghanizadeh, Z. Rezaee, S. Dehbozorgi, M. Berk, and S. Akhondzadeh, “Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial,” Psychiatry Research, 2014. View at Publisher · View at Google Scholar